CA2479638C - Hfa-suspension formulations of crystalline tiotropium bromide anhydrate - Google Patents

Hfa-suspension formulations of crystalline tiotropium bromide anhydrate Download PDF

Info

Publication number
CA2479638C
CA2479638C CA2479638A CA2479638A CA2479638C CA 2479638 C CA2479638 C CA 2479638C CA 2479638 A CA2479638 A CA 2479638A CA 2479638 A CA2479638 A CA 2479638A CA 2479638 C CA2479638 C CA 2479638C
Authority
CA
Canada
Prior art keywords
hfa
acid
contain
suspensions
tiotropium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2479638A
Other languages
English (en)
French (fr)
Other versions
CA2479638A1 (en
Inventor
Christel Schmelzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2479638A1 publication Critical patent/CA2479638A1/en
Application granted granted Critical
Publication of CA2479638C publication Critical patent/CA2479638C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2479638A 2002-03-28 2003-03-20 Hfa-suspension formulations of crystalline tiotropium bromide anhydrate Expired - Fee Related CA2479638C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats
DE10214264.5 2002-03-28
PCT/EP2003/002899 WO2003082244A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats

Publications (2)

Publication Number Publication Date
CA2479638A1 CA2479638A1 (en) 2003-10-09
CA2479638C true CA2479638C (en) 2011-01-04

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2479638A Expired - Fee Related CA2479638C (en) 2002-03-28 2003-03-20 Hfa-suspension formulations of crystalline tiotropium bromide anhydrate

Country Status (21)

Country Link
EP (1) EP1492498A2 (ru)
JP (1) JP5147158B2 (ru)
KR (1) KR101005717B1 (ru)
CN (1) CN1642525A (ru)
AU (1) AU2003221509B2 (ru)
BR (1) BR0308709A (ru)
CA (1) CA2479638C (ru)
DE (1) DE10214264A1 (ru)
EA (1) EA008610B1 (ru)
EC (1) ECSP045322A (ru)
HR (1) HRP20040890A2 (ru)
IL (1) IL163696A0 (ru)
ME (1) ME00246B (ru)
MX (1) MXPA04009338A (ru)
NO (1) NO20044004L (ru)
NZ (1) NZ536030A (ru)
PL (1) PL371295A1 (ru)
RS (1) RS52481B (ru)
UA (1) UA79776C2 (ru)
WO (1) WO2003082244A2 (ru)
ZA (1) ZA200405637B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007144531A (ru) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые кристаллические формы тиотропийбромида
AU2006243238B2 (en) * 2005-05-02 2012-05-24 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
JP6781831B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE50115277D1 (de) * 2000-10-31 2010-02-04 Boehringer Ingelheim Pharma Arzneimittelkompositionen aus tiotropiumsalzen und
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US8703806B2 (en) 2009-05-29 2014-04-22 Pearl Therapeutics, Inc. Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Also Published As

Publication number Publication date
BR0308709A (pt) 2005-01-04
JP2005527550A (ja) 2005-09-15
UA79776C2 (en) 2007-07-25
JP5147158B2 (ja) 2013-02-20
HRP20040890A2 (en) 2005-06-30
RS52481B (en) 2013-02-28
MXPA04009338A (es) 2005-01-25
NZ536030A (en) 2006-07-28
AU2003221509A1 (en) 2003-10-13
EP1492498A2 (de) 2005-01-05
DE10214264A1 (de) 2003-10-16
CN1642525A (zh) 2005-07-20
AU2003221509B2 (en) 2008-01-24
ZA200405637B (en) 2005-07-27
KR101005717B1 (ko) 2011-01-05
WO2003082244A2 (de) 2003-10-09
IL163696A0 (en) 2005-12-18
PL371295A1 (en) 2005-06-13
MEP47308A (en) 2011-02-10
ECSP045322A (es) 2005-01-28
EA200401159A1 (ru) 2005-04-28
ME00246B (me) 2011-05-10
EA008610B1 (ru) 2007-06-29
CA2479638A1 (en) 2003-10-09
WO2003082244A3 (de) 2004-02-05
KR20040098022A (ko) 2004-11-18
YU86004A (sh) 2006-08-17
NO20044004L (no) 2004-10-05

Similar Documents

Publication Publication Date Title
US7736627B2 (en) HFA suspension formulations containing an anticholinergic
CA2450961C (en) Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
MXPA03003221A (es) Monohidrato cristalino, procedmiento para su preparacion y su uso para la preparacion de un medicamento.
CA2544352C (en) Crystalline anhydrate with anticholinergic effect
ZA200602343B (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
ZA200602342B (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
CA2479638C (en) Hfa-suspension formulations of crystalline tiotropium bromide anhydrate
CA2479640C (en) Hfa suspension formulations containing an anticholinergic
US7244415B2 (en) HFA suspension formulations of an anhydrate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831